Related Experiment Video
Updated: Oct 15, 2025
Directed Protein Packaging within Outer Membrane Vesicles from Escherichia coli: Design, Production and Purification
Published on: November 16, 2016
Engineered Remolding and Application of Bacterial Membrane Vesicles
Li Qiao1, Yifan Rao1, Keting Zhu1
1Department of Emergency, Xinqiao Hospital, Army Medical University, Chongqing, China.
Abstract:
Bacterial membrane vesicles (MVs) are produced by both Gram-positive and Gram-negative bacteria during growth in vitro and in vivo. MVs are nanoscale vesicular structures with diameters ranging from 20 to 400 nm. MVs incorporate bacterial lipids, proteins, and often nucleic acids, and can effectively stimulate host immune response against bacterial infections. As vaccine candidates and drug delivery systems, MVs possess high biosafety owing to the lack of self-replication ability. However, wild-type bacterial strains have poor MV yield, and MVs from the wild-type strains may be harmful due to the carriage of toxic components, such as lipopolysaccharides, hemolysins, enzymes, etc. In this review, we summarize the genetic modification of vesicle-producing bacteria to reduce MV toxicity, enhance vesicle immunogenicity, and increase vesicle production. The engineered MVs exhibit broad applications in vaccine designs, vaccine delivery vesicles, and drug delivery systems.
Insights
Engineered bacterial membrane vesicles (MVs) offer enhanced safety and efficacy for vaccines and drug delivery. Genetic modifications improve production, reduce toxicity, and boost immunogenicity of these nanoscale vesicles.
Area of Science:
- Microbiology
- Nanotechnology
- Immunology
Background:
- Bacterial membrane vesicles (MVs) are nanoscale structures released by bacteria.
- MVs contain bacterial components and can modulate host immune responses.
- While promising for biomedical applications, wild-type MVs have limitations like low yield and toxicity.
Purpose of the Study:
- To review genetic modification strategies for bacterial membrane vesicles.
- To enhance MV production, reduce toxicity, and improve immunogenicity.
- To highlight engineered MVs' applications in vaccines and drug delivery.
Main Methods:
- Genetic engineering of vesicle-producing bacterial strains.
- Modification of bacterial pathways to alter MV composition and yield.
- Characterization of engineered MVs for toxicity, immunogenicity, and production levels.
Main Results:
- Engineered MVs demonstrate reduced toxicity compared to wild-type MVs.
- Genetic modifications successfully increased MV production yields.
- Enhanced immunogenicity of engineered MVs was observed, suitable for vaccine development.
Conclusions:
- Genetic modification is a viable strategy to optimize bacterial membrane vesicles for biomedical use.
- Engineered MVs offer improved safety profiles and enhanced therapeutic potential.
- These modified MVs show significant promise as advanced vaccine and drug delivery platforms.
